by Portfolio Grader | May 15, 2013 11:45 am
Five Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
This week, Ariad Pharmaceuticals (NASDAQ:ARIA) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
This is a strong week for Neurocrine Biosciences (NASDAQ:NBIX). The company’s rating climbs to B from the previous week’s C. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Array BioPharma (NASDAQ:ARRY) boosts its rating from a C to a B this week. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. The stock price has risen 8% over the past month, better than the 6.1% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
This week, Celldex Therapeutics (NASDAQ:CLDX) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
Insmed Inc. (NASDAQ:INSM) shows solid improvement this week. The company’s rating rises from a C to a B. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 19% over the past month. For more information, get Portfolio Grader’s complete analysis of INSM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/05/5-biotechnology-stocks-to-buy-now-aria-nbix-arry-9/
Short URL: http://invstplc.com/1nzSnvY
Copyright ©2015 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.